ACTIVE SUBSTANCE / INN

DOXORUBICIN

Brand name(s): Myocet liposomal (previously Myocet), Doxorubicin SUN, Zolsketil pegylated liposomal, Doxolipad, Doxorubicin Hydrochloride Tillomed, Caelyx pegylated liposomal
EMA LISTED
APPLICATION WITHDRAWN
REFUSED
AUTHORISED
Ovarian Neoplasms;Sarcoma, Kaposi;Multiple Myeloma
Breast Neoplasms
ACTIVE SUBSTANCE
Doxorubicin
REGULATORS
EMA
SPONSORS / MAH
CHEPLAPHARM Arzneimittel GmbH, Sun Pharmaceutical Industries Europe B.V., Baxter Holding B.V.
TOTAL APPLICATIONS
6
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Caelyx pegylated liposomalBaxter Holding B.V.Authorised20/06/1996Sarcoma, Kaposi;Multiple Myeloma;Ovarian Neoplasms;Breast Neoplasms
Zolsketil pegylated liposomalAccord Healthcare S.L.U.Authorised31/05/2022Ovarian Neoplasms;Sarcoma, Kaposi;Multiple Myeloma
Myocet liposomal (previously Myocet)CHEPLAPHARM Arzneimittel GmbHAuthorised13/07/2000Breast Neoplasms
Doxorubicin Hydrochloride TillomedLaboratorios Tillomed Spain S.L.UApplication withdrawnBreast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi
DoxolipadTLC Biopharmaceuticals B.V.RefusedBreast Neoplasms;Ovarian Neoplasms
Doxorubicin SUNSun Pharmaceutical Industries Europe B.V.Application withdrawn

FULL INTELLIGENCE ON DOXORUBICIN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →